Defective interferon-augmented natural killer cell activity in patients with metastatic malignant melanoma
Ch. M�ller, Hubert Pehamberger, Michael Binder et al. · Journal of Cancer Research and Clinical Oncology · 1989
Cited by 5 works. doi:10.1007/bf00400969
Authors
References
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
- Natural Killer Cells: Their Roles in Defenses Against Disease
- Augmentation of Mouse Natural Killer Cell Activity by Interferon and Interferon Inducers
- Definitive evidence that natural killer (NK) cells inhibit experimental tumor metastases in vivo.
- Correlation of stress factors with sustained depression of natural killer cell activity and predicted prognosis in patients with breast cancer.
- Prognostic risk assessment in primary breast cancer by behavioral and immunological parameters.
- DTIC therapy in metastatic malignant melanoma: a simplified dose schedule.
- Tumour‐related changes in natural killer cell activity in melanoma patients. Influence of stage of disease, tumour thickness and age of patients
- Defects in natural killer cell activity and interferon response in human lung carcinoma and malignant melanoma.